Eli Lilly’s Zepbound and Mounjaro Sales Missed Estimates Again. The Wobble’s Looking Serious.
The results are an uncomfortable echo of late October 2024, when Mounjaro and Zepbound missed by similar margins. Those results unsettled investors, setting off a three-week sello
Lilly Projects 2024 Revenue Miss as Zepbound, Mounjaro Disappoint
The updated guidance, which was largely driven by lower-than-anticipated sales of GLP-1 blockbusters Mounjaro and Zepbound, sent Eli Lilly’s shares cratering by as much as 8% Tuesday, even as the company forecasted robust 2025 revenue.
Lilly's stock leads S&P 500 losers as Mounjaro, Zepbound sales to miss forecasts
Shares of Eli Lilly were taking a 6.9% hit toward a two-month low in recent trading, enough to make them the S&P 500's biggest decliner. The problem is that the drug giant provided fourth-quarter revenue guidance that was below Wall Street expectations,
Eli Lilly’s stock falls after 2024 guidance misses forecasts
Eli Lilly’s expectations for sales in the fourth quarter of last year missed forecasts, driven by lower-than-expected sales of its diabetes and obesity drugs.
Lilly shares on track for worst day since 2021 after downbeat Zepbound sales forecast
Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street estimates, marking the second time sales have disappointed since the drug's launch in late 2023.
Eli Lilly Stock Falls on Slower Sales Growth of Anti-Obesity Drug
Eli Lilly shares fell after the drugmaker warned that sales of its hot diabetes and anti-obesity drugs are growing more slowly than expected. Lilly now expects fourth-quarter sales of $3.5 billion for diabetes drug Mounjaro and $1.
Eli Lilly Stock Slumps on Lowered Sales Forecast
Key Takeaways Eli Lilly shares tumbled Tuesday after the drugmaker lowered its revenue forecast for the 2024 fiscal year.The maker of weight-loss drugs Mounjaro and Zepbound said sales grew slower than expected in the fourth quarter.
Mounjaro and Zepbound sales disappoint, and Eli Lilly’s stock is dropping
Eli Lilly’s stock was set to suffer its worst day in four years after sales of diabetes and obesity drugs Mounjaro and Zepbound missed expectations.
Lilly forecasts weak fourth-quarter sales of weight-loss drug, shares slump
Eli Lilly forecast sales of popular weight-loss drug Zepbound and related diabetes treatment Mounjaro to miss Wall Street estimates in the fourth quarter, sending the drugmaker's shares down more than 8% on Tuesday.
Eli Lilly Cuts Sales Outlook After Sluggish Growth for Incretin Drugs
Eli Lilly cut its outlook for fourth-quarter revenue citing sluggish growth in the market for incretin, which increases insulin levels.
JD Supra17m
Lilly v. FDA: Two Stories Collide to Make this GLP-1 Case a Tale of Our Time
I recently learned of Eli Lilly & Co.’s (“Lilly”) recent lawsuit against FDA from Nicole DeFeudis, who interviewed me for her ...
As Lilly Stock Tumble on GLP-1 Demand Worries, CEO Says All Is Well
Sales results disclosed Tuesday raised concern that investors may have overestimated the demand for Zepbound and Mounjaro.
Medical News Today29d
How to Get Mounjaro: What to Know About a Mounjaro Prescription Online, According to Our Experts
To approve the generic version of Mounjaro or Zepbound, the FDA will need clear evidence that tirzepatide works as well as the branded medication. Zepbound, which contains the active ingredient ...
BioSpace3h
Dispatches From JPM, Biogen’s Sage Buyout Offer, Pfizer’s Obesity Play, More
J&J, GSK, Eli Lilly and others struck high-value transactions in the early days of biopharma’s annual kickoff conference.
Yahoo Finance6d
LLY Falls Around 14% in 3 Months: How to Play the Stock
Though demand for its popular tirzepatide drugs, Mounjaro and Zepbound, remains massive, their sales were hurt due to inventory issues in the third quarter. This led the shares of the company to ...